John Mosack is the Chief Operating Officer (COO) at Tanvex, bringing over 30 years of operations management experience in the biopharmaceutical industry for both drug substance and drug product facilities. Prior to joining Tanvex, he held pivotal roles at Catalent Biologics, Lonza, Inc., Bristol-Myers Squibb, and PAREXEL. His extensive expertise spans various biologic modalities (antibodies, cell, and gene therapy) as well as technology platforms (mammalian, microbial fermentation). John has led organizations successfully through state-of-the-art facility start- ups, drug development lifecycle transitions (clinical to commercial), multiple product licensures, operational efficiencies, and technology transitions. John believes a key to success is cultivating a focused, collaborative, and diverse team aligned with the strategic plan of an organization.